IPSIS Provides Blue Cross & Blue Shield of Minnesota with RF Ablation of Peripheral Nerves Evidence

On November 13, 2019, IPSIS offered evidence to Blue Cross and Blue Shield of Minnesota in support of coverage for radiofrequency ablation of the genicular nerves associated with knee osteoarthritis and of the third occipital nerve (C2-3) associated with cervicogenic headache. The Society’s comments refute classification of these procedures as investigational and advocate for coverage in appropriately selected patients.

Under the policy, Radiofrequency Ablation of Peripheral Nerves to Treat Pain, patients covered by Blue Cross and Blue Shield of Minnesota are denied effective, nonsurgical RFA treatments proven to improve patient function and quality of life; decrease dependence on oral pain medications; reduce physical therapy utilization; and spare many future costly and unnecessary surgical interventions.

Acknowledging the strength and quality of the evidence in support of the safety and effectiveness of genicular nerve RFA, the American Medical Association’s Current Procedural Terminology (CPT®) Editorial Panel has approved a Category I code that is expected to go into effect on January 1, 2020.

Members may click here 🔒  to read the IPSIS comment letter.